Clinical Trial Update: Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial assessing modulation of SERCA2a to improve intra-myocytic calcium trafficking in Duchenne muscular dystrophy-associated dilated cardiomyo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy
• Duchenne Muscular Dystrophy

Drugs mentioned

• SERCA2a modulator (experimental) (SERCA2a modulator)

Snippet

Sponsor: Sardocor Corp. | Conditions: DMD-Associated Dilated Cardiomyopathy | Phase 1 | Status: RECRUITING